X4 Pharmaceuticals, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $381.1M
- Price
- $4.04
- % Change (Daily % change from the live per-ticker quote feed.)
- +0.25%
- Volume
- 1.2M
About
X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase Ib clinical trial to treat chronic neutropenia and Waldenström macroglobulinemia. The company is also developing X4P-002, a CXCR4 antagonist for the treatment of brain cancers; and X4P-003, a CXCR4 antagonist for the treatment of CXCR4 disorders and primary immunodeficiencies. It has a license agreement with Abbisko Therapeutics Co., Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company was founded in 2010 and is headquartered in Boston, Massachusetts.
Quick stats
Shares outstanding94.3M
Computed float48.5M
Float / shares51.4%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001501697
Websitehttps://www.x4pharma.com
AI Summary
AI-generated1/17
majorbullishearnings
X4 Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update
X4 Pharmaceuticals reported Q2 2026 revenue of $8.8 million, driven by $6.4 million in license revenue from partner Norgine and $2.4 million in U.S. product sales of XOLREMDI. Net loss narrowed to $16.2 million, or $0.13 per share, from $25.7 million in the prior year, as the company reduced operating expenses following a 2025 restructuring.
The European Commission granted marketing authorization for XOLREMDI for WHIM syndrome, establishing it as the first and only authorized treatment in the EU. Commercialization will be led by Norgine under an agreement that includes up to €221 million in potential milestones for X4.
With $208.0 million in cash, the company has secured a runway into 2029. Operations are focused on the Phase 3 4WARD trial in chronic neutropenia, with management expecting an FDA update on sample size and enrollment completion by the end of Q3.
Red flags
- Weighted average shares outstanding increased approximately 17x year-over-year to 126.3 million, indicating significant dilution or corporate action.